Vigabatrin 500mg Tablet in India: Get the Best Price For this Rare Medicine
Vigabatrin tab/ sachet, brand name Sabril, is a medication that belongs to the class of medicines knowns as antiepileptic drugs (AED). This is rare medicine which is used in the treatment of epilepsy (seizures) and infantile spasms. Sabril Vigabatrin is an imported medicine with very limited suppliers in India. The medicine works by increasing the action of GABA, a chemical messenger, which further suppresses the abnormal activity of the nerve cells in the brain thereby treating seizures. Want to find the best place to purchase Vigabatrin 500mg Tablet in India? Well, continue reading further!
Vigabatrin 500mg Tablet in India
There have been several cases of epilepsy (seizures) and infantile spasms in India, wherein this effective medication has not been available or has been supplied late hampering the immediate treatment. Hence, JollyRX, an online platform, came to the rescue, by making available hard-to-find drugs readily accessible at an affordable price, that too a to your doorstep! Our aim at JollyRX has been to build a platform for readily accessible rare drugs so that no other patient and their family have to face the struggles of procuring them. Hence Vigabatrin 500 mg tablet in India is sold by us under the brand name JolVIG. All you need to do is, type in your required medicine on our website, and send a product inquiry. Our team will get back to you at the earliest with further details!
What are the Benefits of Vigabatrin 500mg Tablet?
The Vigabatrin Tab has proven benefits, mainly as an add-on agent, by treating complex partial and secondarily generalized seizures in both adults and children as well as in infantile spasms. The medication works by averting the breakdown of a natural calming substance known as GABA in the brain, thereby calming the brain.
Key Takeaways
We hope that our article has been insightful and informative. If you have any further queries with regards to hard-to-find drugs, feel free to reach out to us here!
0 Comment